MEDEXUS PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.65 CAD | +6.45% |
|
+4.43% | -33.20% |
| Sales 2024 * | 154M 112M | Sales 2025 * | 155M 112M | Capitalization | 40.36M 29.34M |
|---|---|---|---|---|---|
| Net income 2024 * | -1M -727K | Net income 2025 * | 1M 727K | EV / Sales 2024 * | 0.26 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.26 x |
| P/E ratio 2024 * |
-23.1
x | P/E ratio 2025 * |
10.9
x | Employees | 98 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Medexus Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | +6.45% | ||
| 1 week | +4.43% | ||
| Current month | +2.48% | ||
| 1 month | +8.55% | ||
| 3 months | -34.00% | ||
| 6 months | -31.25% | ||
| Current year | -33.20% |
1 week
1.47
1.70
1 month
1.471.76
Current year
1.473.16
1 year
1.123.53
3 years
0.888.25
5 years
0.889.75
10 years
0.889.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 18-10-15 | |
Marcel Konrad
DFI | Director of Finance/CFO | 49 | 21-07-18 |
Richard Labelle
COO | Chief Operating Officer | - | 14-02-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Adele Gulfo
BRD | Director/Board Member | 61 | 19-06-24 |
Michael Mueller
CHM | Chairman | 64 | 14-05-30 |
Benoit Gravel
BRD | Director/Board Member | - | 17-09-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.65 | +6.45% | 74,660 |
| 24-04-18 | 1.55 | +2.65% | 51,716 |
| 24-04-17 | 1.51 | -1.95% | 41,094 |
| 24-04-16 | 1.54 | -1.28% | 26,610 |
| 24-04-15 | 1.56 | -1.27% | 70,356 |
Delayed Quote Toronto S.E., April 19, 2024 at 03:57 pm EDT
More quotes
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The divisionâs prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The divisionâs products include Rasuvo, IXINITY and Gleolan.
Sector
Pharmaceuticals
Calendar
2024-06-18
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.65
CAD
Average target price
3.208
CAD
Spread / Average Target
+94.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.20% | 29.37M | |
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.69% | 147B | |
| -6.63% | 144B |
- Stock Market
- Equities
- MDP Stock
